Pfizer Canada/HSFC Research Fellowship - McCarter


Dr. Sarah McCarter
St. Michael's Hospital 

Dr. Sarah McCarter is undertaking an ambitious three-year study on the use of gene therapy to treat Acute Respiratory Distress Syndrome (ARDS). This disease, in which blood vessel and airway inflammation results in severe lung injury, is a common cause of disability and death in critical care units. Studies have estimated the ARDS mortality rate to be between 40 and 50 per cent.
 
Dr. McCarter believes that gene therapy, which may slow the progression of ARDS by protecting blood vessels from inflammation, could lead to a new treatment for the disease.
 
Dr. McCarter’s study will also provide an important foundation for the treatment of other vascular inflammatory diseases, since protection of the blood vessels in ARDS patients may translate to blood vessel protection following heart attacks and in illnesses such as congestive heart failure.
 
Dr. McCarter is a postdoctoral research fellow, working under the supervision of Dr. Duncan Stuart, in the cardiology division at St. Michael’s Hospital in Toronto.
 
The Heart and Stroke Foundation of Canada and Pfizer Canada Inc. congratulate Dr. McCarter and look forward to the outcome of her innovative work.
 
Supported by Pfizer Canada

 

English